DK3505528T3 - Modulation af hepatitis-b-virus (hbv)-ekspression - Google Patents

Modulation af hepatitis-b-virus (hbv)-ekspression Download PDF

Info

Publication number
DK3505528T3
DK3505528T3 DK19155538.2T DK19155538T DK3505528T3 DK 3505528 T3 DK3505528 T3 DK 3505528T3 DK 19155538 T DK19155538 T DK 19155538T DK 3505528 T3 DK3505528 T3 DK 3505528T3
Authority
DK
Denmark
Prior art keywords
hbv
hepatitis
virus
modulation
expression
Prior art date
Application number
DK19155538.2T
Other languages
Danish (da)
English (en)
Inventor
Eric E Swayze
Susan M Freier
Michael L Mccaleb
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47041953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3505528(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3505528T3 publication Critical patent/DK3505528T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK19155538.2T 2011-04-21 2012-04-20 Modulation af hepatitis-b-virus (hbv)-ekspression DK3505528T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161478040P 2011-04-21 2011-04-21
US201161478038P 2011-04-21 2011-04-21
US201261596692P 2012-02-08 2012-02-08
US201261596690P 2012-02-08 2012-02-08
EP17186598.3A EP3312189A1 (en) 2011-04-21 2012-04-20 Modulation of hepatitis b virus (hbv) expression

Publications (1)

Publication Number Publication Date
DK3505528T3 true DK3505528T3 (da) 2021-02-08

Family

ID=47041953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19155538.2T DK3505528T3 (da) 2011-04-21 2012-04-20 Modulation af hepatitis-b-virus (hbv)-ekspression

Country Status (35)

Country Link
US (7) US8642752B2 (enExample)
EP (4) EP3505528B1 (enExample)
JP (3) JP6042871B2 (enExample)
KR (3) KR102247463B1 (enExample)
CN (3) CN103582648B (enExample)
AU (1) AU2012245243B2 (enExample)
CA (1) CA2833766C (enExample)
CL (1) CL2013003053A1 (enExample)
CO (1) CO6862103A2 (enExample)
CR (2) CR20190207A (enExample)
CY (1) CY1124327T1 (enExample)
DK (1) DK3505528T3 (enExample)
DO (1) DOP2013000246A (enExample)
EA (1) EA029137B1 (enExample)
ES (1) ES2856266T3 (enExample)
HR (1) HRP20210244T1 (enExample)
HU (1) HUE053401T2 (enExample)
IL (2) IL228874B (enExample)
LT (1) LT3505528T (enExample)
MX (2) MX347253B (enExample)
MY (1) MY169474A (enExample)
NZ (2) NZ616512A (enExample)
PE (2) PE20181267A1 (enExample)
PH (2) PH12019502377A1 (enExample)
PL (1) PL3505528T3 (enExample)
PT (1) PT3505528T (enExample)
RS (1) RS61447B1 (enExample)
RU (1) RU2667524C2 (enExample)
SG (2) SG194555A1 (enExample)
SI (1) SI3505528T1 (enExample)
SM (1) SMT202100084T1 (enExample)
TW (1) TWI548745B (enExample)
UA (1) UA118951C2 (enExample)
WO (1) WO2012145697A1 (enExample)
ZA (1) ZA201307620B (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
JP5665317B2 (ja) 2006-10-18 2015-02-04 アイシス ファーマシューティカルズ， インコーポレーテッド アンチセンス化合物
WO2011053982A2 (en) 2009-11-02 2011-05-05 University Of Washington Therapeutic nuclease compositions and methods
EP3587574B1 (en) * 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2673361B1 (en) 2011-02-08 2016-04-13 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
JP6063450B2 (ja) 2011-04-29 2017-01-18 ユニヴァーシティ オブ ワシントン 治療用ヌクレアーゼ組成物および方法
CN106434665B (zh) 2011-06-30 2021-06-08 箭头药业股份有限公司 用于抑制乙型肝炎病毒的基因表达的组合物和方法
WO2013022967A1 (en) 2011-08-11 2013-02-14 Isis Pharmaceuticals, Inc. Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof
EP2839006B1 (en) 2012-04-20 2018-01-03 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US8802697B2 (en) 2012-07-11 2014-08-12 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
JP6270846B2 (ja) 2012-08-30 2018-01-31 レプリコール インコーポレーティッド Ｂ型肝炎感染及びｄ型肝炎感染の治療方法
EP2906699A4 (en) 2012-10-11 2016-06-08 Ionis Pharmaceuticals Inc OLIGOMER COMPOUNDS WITH BICYCLIC NUCLEOSIDES AND USES THEREOF
US10577604B2 (en) 2012-10-15 2020-03-03 Ionis Pharmaceuticals, Inc. Methods for monitoring C9ORF72 expression
FI2906696T4 (fi) 2012-10-15 2023-03-18 Menetelmiä c9orf72:n ilmentymisen moduloimiseksi
BR112015008399A8 (pt) 2012-10-15 2017-10-03 Ionis Pharmaceuticals Inc Composto para modular a expressão de c90rf72, seu uso, oligonucleotídeo modificado, composto de fita dupla e composição
SG11201503821YA (en) 2012-11-15 2015-06-29 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
RU2649367C2 (ru) 2013-01-30 2018-04-02 Ф. Хоффманн-Ля Рош Аг Конъюгаты углевода и lna-олигонуклеотида
KR102482890B1 (ko) 2013-05-01 2022-12-30 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법
US9943604B2 (en) 2013-09-20 2018-04-17 Ionis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
MY192689A (en) 2013-10-11 2022-09-01 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
AU2014339972B9 (en) 2013-10-25 2019-05-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
HRP20192080T1 (hr) 2013-10-31 2020-02-07 Resolve Therapeutics, Llc Terapeutske fuzije nukleaza-albumine i postupci
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
MY192634A (en) 2014-04-01 2022-08-29 Biogen Ma Inc Compositions for modulating sod-1 expression
SI3137605T1 (sl) 2014-05-01 2021-02-26 Ionis Pharmaceuticals, Inc. Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
PE20170010A1 (es) 2014-05-01 2017-03-04 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion del factor b del complemento
GB201408623D0 (en) * 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP2966170A1 (en) * 2014-07-10 2016-01-13 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - HBV inactivation
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
EA202191771A1 (ru) * 2015-03-24 2022-01-31 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ RNAi ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP6606557B2 (ja) * 2015-04-16 2019-11-13 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｃ９ｏｒｆ７２発現を調節するための組成物
AU2016296592B2 (en) 2015-07-17 2021-08-19 Arcturus Therapeutics, Inc. Compositions and agents against Hepatitis B virus and uses thereof
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
CA2999341A1 (en) 2015-11-06 2017-05-11 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
CN109069529B (zh) 2016-03-07 2021-08-20 箭头药业股份有限公司 用于治疗性化合物的靶向配体
AR108038A1 (es) 2016-03-14 2018-07-11 Roche Innovation Ct Copenhagen As Oligonucleótidos para reducir la expresión de pd-l1 (ligando de muerte programada-1)
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
DK3478830T3 (da) 2016-07-01 2024-05-21 Resolve Therapeutics Llc Optimerede binucleasefusioner og metoder
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
CN109462981B (zh) 2016-09-02 2023-07-07 箭头药业股份有限公司 靶向配体
WO2018053185A1 (en) * 2016-09-14 2018-03-22 Alios Biopharma, Inc. Modified oligonucleotides and methods of use
CN109661233A (zh) 2016-10-06 2019-04-19 Ionis 制药公司 缀合低聚化合物的方法
CN110234763A (zh) * 2016-11-11 2019-09-13 詹森生物制药有限公司 针对hbv cccdna的寡核苷酸靶向策略
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CA3047076A1 (en) * 2016-12-13 2018-06-21 Am Sciences Inc Pharmaceutical composition for preventing or treating hepatitis b
CA3046504A1 (en) 2016-12-15 2018-06-21 Meharry Medical College Antiviral agents
CN106729753A (zh) * 2016-12-16 2017-05-31 谭旭 抗乙型肝炎病毒的递送系统和生物制剂
CN106701763B (zh) * 2016-12-30 2019-07-19 重庆高圣生物医药有限责任公司 CRISPR/Cas9靶向敲除人乙肝病毒P基因及其特异性gRNA
CN106916905B (zh) * 2017-01-17 2018-06-08 重庆医科大学附属儿童医院 隐匿性乙肝病毒检测试剂盒及其检测方法
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
SG11201909572QA (en) 2017-04-18 2019-11-28 Alnylam Pharmaceuticals Inc Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
JP7374091B2 (ja) 2017-08-22 2023-11-06 サナバイオ， エルエルシー 可溶性インターフェロン受容体およびその使用
US11555191B2 (en) 2017-09-01 2023-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibitor for use for preventing and/or treating an infection with hepatitis B virus
AU2018350693B2 (en) 2017-10-16 2021-03-04 F. Hoffmann-La Roche Ag Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
SG11202003488WA (en) 2017-10-20 2020-05-28 Dicerna Pharmaceuticals Inc Methods for treating hepatitis b infection
AU2019218987B2 (en) 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
EP3775208A1 (en) 2018-04-05 2021-02-17 F. Hoffmann-La Roche AG Use of fubp1 inhibitors for treating hepatitis b virus infection
MY206038A (en) 2018-07-03 2024-11-26 Hoffmann La Roche Oligonucleotides for modulating tau expression
MX2021000404A (es) 2018-07-13 2021-03-25 Hoffmann La Roche Oligonucleotidos para modular la expresion de rtel1.
UA127745C2 (uk) 2018-08-13 2023-12-20 Альнілам Фармасьютікалз, Інк. КОМПОЗИЦІЇ, ЩО МІСТЯТЬ ЗАСІБ НА ОСНОВІ dsRNA ВІРУСУ ГЕПАТИТУ В (HBV), ТА СПОСОБИ ЇХ ВИКОРИСТАННЯ
CN109234275A (zh) * 2018-08-30 2019-01-18 山东省立医院 一种可以同时抑制乙肝病毒dna和乙肝表面抗原的反义核苷酸
US20220339281A1 (en) * 2019-03-05 2022-10-27 GalxoSmithKline Biologicals SA Hepatitis b immunisation regimen and compositions
BR112021019182A2 (pt) * 2019-04-03 2022-05-31 Bristol Myers Squibb Co Oligonucleotídeos angptl2 antissenso e seus usos
SG11202112741XA (en) * 2019-05-31 2021-12-30 Aligos Therapeutics Inc Modified gapmer oligonucleotides and methods of use
WO2021107097A1 (ja) * 2019-11-28 2021-06-03 株式会社ボナック Ｂ型肝炎治療用核酸分子
JP2023506954A (ja) 2019-12-19 2023-02-20 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
EP4077670A1 (en) 2019-12-19 2022-10-26 F. Hoffmann-La Roche AG Use of cops3 inhibitors for treating hepatitis b virus infection
CN114829599A (zh) 2019-12-19 2022-07-29 豪夫迈·罗氏有限公司 Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
CN114901821A (zh) 2019-12-19 2022-08-12 豪夫迈·罗氏有限公司 Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
JP2023506550A (ja) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用
WO2021226019A2 (en) * 2020-05-04 2021-11-11 The Regents Of The University Of California Compositions and methods for treating viral infections
TW202223089A (zh) * 2020-07-27 2022-06-16 美商艾利格斯醫療公司 與hbv結合之寡核苷酸及使用方法
EP4200419A2 (en) 2020-08-21 2023-06-28 F. Hoffmann-La Roche AG Use of a1cf inhibitors for treating hepatitis b virus infection
CN114507663A (zh) * 2020-11-16 2022-05-17 浙江柏拉阿图医药科技有限公司 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用
TW202246500A (zh) 2021-02-02 2022-12-01 瑞士商赫孚孟拉羅股份公司 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
CA3219942A1 (en) * 2021-05-10 2022-11-17 Q-State Biosciences, Inc. Compositions targeting sodium channel 1.6
KR20240111795A (ko) * 2021-11-29 2024-07-17 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법
JP2024546993A (ja) 2021-12-17 2024-12-26 エフ． ホフマン－ラ ロシュ アーゲー Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ
AU2023205244A1 (en) * 2022-01-10 2024-06-27 Ausperbio Therapeutics Inc. Modulation of hepatitis b virus (hbv) expression
AU2023213173A1 (en) 2022-01-28 2024-08-01 Glaxosmithkline Intellectual Property Development Limited Combination therapy for treating hepatitis b virus infections
WO2023187612A1 (en) 2022-03-29 2023-10-05 Glaxosmithkline Intellectual Property Development Limited Method of treating chronic hepatitis b
WO2024214041A1 (en) 2023-04-12 2024-10-17 Glaxosmithkline Intellectual Property Development Limited Methods of treating chronic hepatitis b
WO2025031485A1 (zh) * 2023-08-10 2025-02-13 石药集团中奇制药技术（石家庄）有限公司 一种抑制HBV基因表达的dsRNA分子及其应用
CN118667808B (zh) * 2023-08-22 2025-04-18 浙江柏拉阿图医药科技有限公司 双‐Gap修饰寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用
WO2025061204A1 (zh) * 2023-09-21 2025-03-27 华辉安健（北京）生物科技有限公司 用于hbv相关疾病的化合物及其应用
WO2025242321A1 (en) 2024-05-24 2025-11-27 Glaxosmithkline Intellectual Property (No.3) Limited Novel use

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US4806463A (en) 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5780219A (en) 1989-07-11 1998-07-14 Gen-Probe Incorporated Nucleic acid amplification oligonucleotides and probes to human hepatitis B virus
GB9006924D0 (en) 1990-03-28 1990-05-23 Imperial College Prognosis of hepatitis infection
JPH05506993A (ja) 1990-04-20 1993-10-14 ザ・ジェネラル・ホスピタル・コーポレーション ウイルスの複製を防止する方法
US5610050A (en) 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
RU2142467C1 (ru) * 1990-07-27 1999-12-10 Чирон Диагностикс Корпорейшн Полинуклеотиды, способ их получения, гибридизационный анализ нуклеиновой кислоты
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
ATE199158T1 (de) 1991-12-23 2001-02-15 Bayer Ag Hbv amplifizierungssonden zur verwendung in hybridisierungssandwichassay in der lösungsphase
US20030068301A1 (en) * 1992-05-14 2003-04-10 Kenneth Draper Method and reagent for inhibiting hepatitis B virus replication
US6017756A (en) 1992-05-14 2000-01-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting hepatitis B virus replication
US20040054156A1 (en) * 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
WO2002081494A1 (en) 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US20040127446A1 (en) 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
US5736334A (en) 1993-04-12 1998-04-07 Abbott Laboratories Nucleotide sequences and process for amplifying and detection of hepatitis B viral DNA
WO1995002690A1 (en) 1993-07-13 1995-01-26 Abbott Laboratories Nucleotide sequences and process for amplifying and detection of hepatitis b virus
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
JPH09507062A (ja) * 1993-12-23 1997-07-15 アポロン インク． 抗ｂ型肝炎ウイルスオリゴヌクレオチド
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
GB9401987D0 (en) 1994-02-02 1994-03-30 Imperial College Modified nucleic acid
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US5856459A (en) * 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6217858B1 (en) 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
US5843770A (en) * 1996-03-11 1998-12-01 The Immune Response Corporation Antisense constructs directed against viral post-transcriptional regulatory sequences
ZA973367B (en) 1996-04-19 1997-11-18 Innogenetics Nv Method for typing and detecting HBV.
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
DE19725803C1 (de) 1997-06-18 1999-02-11 Deutsches Krebsforsch HBV-gerichtete Antisense-Nukleinsäuren
CN1057302C (zh) * 1997-08-27 2000-10-11 中国科学院上海生物化学研究所 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
KR100414936B1 (ko) 1997-09-12 2004-01-13 엑시콘 에이/에스 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
CN1081069C (zh) * 1998-08-14 2002-03-20 饶纬华 乙型肝炎治疗性疫苗及其制备方法
PT1178999E (pt) 1999-05-04 2007-06-26 Santaris Pharma As Análogos de l-ribo-lna
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US20040002153A1 (en) * 1999-07-21 2004-01-01 Monia Brett P. Modulation of PTEN expression via oligomeric compounds
JP2004512810A (ja) 1999-08-31 2004-04-30 サーナ・セラピューティクス・インコーポレイテッド 核酸に基づく遺伝子発現の調節剤
WO2001038498A2 (en) 1999-11-24 2001-05-31 Pharmasset, Ltd. A new genotype of hepatitis b virus
HK1048492A1 (zh) 1999-12-03 2003-04-04 Innogenetics N.V. 新的hbv序列
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
EP1152063A1 (en) 2000-05-03 2001-11-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Method of diagnosing HBV infection stages
AU2001269092A1 (en) 2000-06-27 2002-01-08 Axxima Pharmaceuticals Ag Inhibitors of hepatitis b virus infection
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
US20080161256A1 (en) 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
WO2003031934A2 (en) 2001-10-09 2003-04-17 Chiron Corporation Identification of oligonucleotides for the capture, detection and quantitation of hepatitis b viral dna
US6828105B2 (en) 2001-10-16 2004-12-07 Avi Biopharma, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20050266422A1 (en) 2002-02-20 2005-12-01 Sirna Therapeutics, Inc. Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides
EP2033967A1 (en) 2002-04-12 2009-03-11 Melbourne Health Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
US7015317B2 (en) 2002-05-02 2006-03-21 Abbott Laboratories Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids
EP2292801B1 (en) 2002-06-14 2018-08-08 Gen-Probe Incorporated Compositions and methods for detecting hepatitis b virus
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
BR0314259A (pt) 2002-09-13 2005-07-26 Idenix Cayman Ltd ß-l-2'-desoxinucleosìdeos para o tratamento de cepas de hbv resistentes e terapias combinadas
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP1560840B1 (en) 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US7511131B2 (en) * 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
DK2284266T3 (da) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
EP1597351B1 (en) 2003-02-27 2012-04-18 Alnylam Pharmaceuticals Inc. METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES
CN1257284C (zh) 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
US20040191776A1 (en) 2003-03-21 2004-09-30 Pei-Jer Chen Method for genotyping and quantifying Hepatitis B Virus
US20040185452A1 (en) 2003-03-21 2004-09-23 Pei-Jer Chen Identification of single nucleotide polymorphisms
US7067249B2 (en) 2003-05-19 2006-06-27 The University Of Hong Kong Inhibition of hepatitis B virus (HBV) replication by RNA interference
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
BRPI0411219A (pt) 2003-06-12 2006-07-18 Nucleonics Inc seqüências de hbv e hcv conservadas úteis para silenciamento de gene
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
EP1493822A1 (de) 2003-07-02 2005-01-05 Labor Becker, Olgemoeller & Kollegen GbR Detektionsverfahren für Nucleinsäuren mit interner Amplifikationskontrolle
KR100647277B1 (ko) 2003-08-14 2006-11-17 삼성전자주식회사 Ｂ형 간염 검사용 ｐｃｒ 프라이머 세트 및 이를 포함하는 ｂ형 간염 검사 키트
US7521184B2 (en) 2003-08-22 2009-04-21 Sirna Therapeutics, Inc. Detection and quantitation of nucleic acid molecules in biological samples
JP4731324B2 (ja) 2003-08-28 2011-07-20 武 今西 Ｎ−ｏ結合性架橋構造型新規人工核酸
DE10339927A1 (de) 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
US20080207539A1 (en) 2003-09-01 2008-08-28 Patrick Arbuthnot Self-Processing Rna Expression Cassette
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
ES2332712T3 (es) 2003-12-16 2010-02-11 Bio-Rad Pasteur Oligonucleotidos para la deteccion del virus de la hepatitis b.
JP2007520461A (ja) 2003-12-16 2007-07-26 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 肝炎ウイルスの負荷を変えるための方法および化合物
AU2005248147A1 (en) 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
JP2008504840A (ja) * 2004-06-30 2008-02-21 アルニラム ファーマスーティカルズ インコーポレイテッド 非リン酸骨格結合を含むオリゴヌクレオチド
ATE503830T1 (de) 2004-09-28 2011-04-15 Melbourne Health Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon
WO2006039739A1 (en) 2004-10-13 2006-04-20 Melbourne Health Hepatitis b viral (hbv) mutants detection and application
WO2006069064A2 (en) 2004-12-22 2006-06-29 Nucleonics, Inc. Conserved hbv and hcv sequences useful for gene silencing
EP1696040A1 (en) 2005-02-28 2006-08-30 Eurofins Viralliance, Inc. Method of genotyping and phenotyping hepatitis B viruses resistant to antiviral molecules
US20060205040A1 (en) 2005-03-03 2006-09-14 Rangarajan Sampath Compositions for use in identification of adventitious viruses
US20080096839A1 (en) 2005-03-09 2008-04-24 Mogam Biotechnology Research Institute Small Interfering Rna and Pharmaceutical Composition for Treatment of Hepatitis B Comprising the Same
US20060258610A1 (en) * 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
GB0519169D0 (en) 2005-09-21 2005-10-26 Leuven K U Res & Dev Novel anti-viral strategy
GB0522578D0 (en) 2005-11-04 2005-12-14 King S College London Ribozymal nucleic acid
WO2007078029A1 (en) 2006-01-05 2007-07-12 Catch By Gene Co., Ltd. A quantitative method for hbv-dna, a primer and probe for detecting hbv-dna, and a detecting kit comprising the same
WO2007084567A2 (en) 2006-01-17 2007-07-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Detection and discrimination of hepatitis c virus, human immunodeficiency virus type-1 and hepatitis b virus
EP2161038B1 (en) 2006-01-26 2013-12-25 Isis Pharmaceuticals, Inc. Compositions and their uses directed to Huntingtin
ES2516815T3 (es) 2006-01-27 2014-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en la posición 6
US8178503B2 (en) 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
WO2008011473A2 (en) * 2006-07-19 2008-01-24 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hbxip
PT1911852E (pt) 2006-10-12 2009-10-09 Bio Rad Pasteur Sondas de cadeia dupla para a detecção fluorescente de ácidos nucleicos
JP5665317B2 (ja) * 2006-10-18 2015-02-04 アイシス ファーマシューティカルズ， インコーポレーテッド アンチセンス化合物
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
CN101589143A (zh) * 2006-11-27 2009-11-25 Isis药物公司 用于治疗高胆固醇血症的方法
CA2673622A1 (en) 2006-12-22 2008-07-03 Imuthes Limited Lipid
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
US20100015218A1 (en) 2007-02-16 2010-01-21 Vasant Jadhav Compositions and methods for potentiated activity of biologically active molecules
WO2008119000A1 (en) 2007-03-27 2008-10-02 University Of Iowa Research Foundation Zinc-finger nuclease and rna interference mediated inactivation of viral genomes
EP2164965B1 (en) * 2007-05-29 2013-09-11 University Of The Witwatersrand, Johannesburg A primary micro rna expression cassette
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US9434997B2 (en) 2007-08-24 2016-09-06 Lawrence Livermore National Security, Llc Methods, compounds and systems for detecting a microorganism in a sample
US20100209491A1 (en) 2007-09-17 2010-08-19 Mogam Biotechnology Research Institute Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv
US20100255482A1 (en) 2007-11-06 2010-10-07 Siemens Healthcare Diagnostics Inc. Hepatitis B Virus (HBV) Specific Oligonucleotide Sequences
KR20100105648A (ko) * 2007-12-03 2010-09-29 엔즌 파마슈티칼스, 인코포레이티드 Ｐｉｋ３ｃａ 발현 조절용 ｒｎａ 길항제 화합물
US20100317599A1 (en) * 2008-02-13 2010-12-16 Alrik Pieter Los Process for the production of a peptide
CN101565756B (zh) 2008-04-25 2013-07-10 中山大学达安基因股份有限公司 一种乙型肝炎病毒核苷类似物耐药相关突变检测试剂盒
CN101603042B (zh) * 2008-06-13 2013-05-01 厦门大学 可用于乙型肝炎病毒感染治疗的rna干扰靶点
US20100015708A1 (en) 2008-06-18 2010-01-21 Mdrna, Inc. Ribonucleic acids with non-standard bases and uses thereof
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
US8293474B2 (en) 2008-07-02 2012-10-23 National Health Research Institutes Oligonucleotides and use thereof for determining deletion in HBV Pre-S region
WO2010012244A1 (zh) 2008-08-01 2010-02-04 苏州瑞博生物技术有限公司 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用
CN104212799B (zh) 2008-10-15 2018-11-23 Ionis制药公司 因子11表达的调节
US20100211327A1 (en) 2009-02-03 2010-08-19 Prosetta Bioconformatics, Inc. Methods and Systems for Viral Diagnosis
US8815514B2 (en) 2009-07-02 2014-08-26 Co-Diagnostics, Inc. Detection primers for nucleic acid extension or amplification reactions
EP2512491B1 (en) 2009-10-16 2017-10-11 Glaxo Group Limited Hbv antisense inhibitors
US9410189B2 (en) 2010-04-30 2016-08-09 Co-Diagnostics, Inc. Methods of preventing non-specific reactions of nucleotide sequences
US20130137090A1 (en) 2010-07-06 2013-05-30 Aptateck Bio Ltd. Nucleic acid aptamer-based diagnostic methods with novel techniques for signal enhancement
EP3587574B1 (en) * 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
WO2012045894A1 (es) 2010-10-05 2012-04-12 Proyecto De Biomedicina Cima, S.L. Compuestos y composiciones para el tratamiento de enfermedades debidas a la infección por el virus de la hepatitis b
RS58982B1 (sr) 2010-10-28 2019-08-30 Benitec Biopharma Ltd Lečenje hbv
EP2673361B1 (en) 2011-02-08 2016-04-13 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
TW201303013A (zh) 2011-04-21 2013-01-16 Isis Pharmaceuticals Inc Ｂ型肝炎病毒（ｈｂｖ）表現之調節
CN106434665B (zh) 2011-06-30 2021-06-08 箭头药业股份有限公司 用于抑制乙型肝炎病毒的基因表达的组合物和方法
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
US11511972B1 (en) 2019-09-26 2022-11-29 Versatile, Inc. System for tracking lifting events at a construction site

Also Published As

Publication number Publication date
MX2013012196A (es) 2014-10-06
PT3505528T (pt) 2021-02-23
EA201391572A1 (ru) 2014-06-30
ZA201307620B (en) 2014-08-27
MY169474A (en) 2019-04-12
DOP2013000246A (es) 2014-04-30
US9127278B2 (en) 2015-09-08
ES2856266T3 (es) 2021-09-27
CN111172162A (zh) 2020-05-19
CR20190207A (es) 2019-06-26
MX340408B (es) 2016-07-07
PH12019502377A1 (en) 2022-11-14
RU2667524C2 (ru) 2018-09-21
AU2012245243A1 (en) 2013-05-02
JP2019022521A (ja) 2019-02-14
TW201249988A (en) 2012-12-16
EP3816288A2 (en) 2021-05-05
JP6426678B2 (ja) 2018-11-21
TWI548745B (zh) 2016-09-11
UA118951C2 (uk) 2019-04-10
BR112013027046A2 (pt) 2016-11-29
KR20190140485A (ko) 2019-12-19
LT3505528T (lt) 2021-04-26
NZ616512A (en) 2015-05-29
KR102247463B1 (ko) 2021-05-04
PL3505528T3 (pl) 2021-08-02
CN103582648B (zh) 2016-08-31
SMT202100084T1 (it) 2021-03-15
US20220064650A1 (en) 2022-03-03
US9034841B2 (en) 2015-05-19
HUE053401T2 (hu) 2021-06-28
IL228874B (en) 2019-08-29
PE20141177A1 (es) 2014-09-19
EP2699583A4 (en) 2015-04-15
BR112013027046A8 (pt) 2017-10-03
PH12013502157B1 (en) 2017-05-29
JP2017046713A (ja) 2017-03-09
US9677076B2 (en) 2017-06-13
CN106191060B (zh) 2020-03-31
US20170369883A1 (en) 2017-12-28
EA029137B1 (ru) 2018-02-28
SG194555A1 (en) 2013-12-30
US8642752B2 (en) 2014-02-04
SG10201604074TA (en) 2016-07-28
CN103582648A (zh) 2014-02-12
US20200190520A1 (en) 2020-06-18
CO6862103A2 (es) 2014-02-10
JP2014513954A (ja) 2014-06-19
CY1124327T1 (el) 2022-07-22
EP3505528B1 (en) 2020-11-25
EP2699583A1 (en) 2014-02-26
AU2012245243B2 (en) 2015-03-12
SI3505528T1 (sl) 2021-04-30
PH12013502157A1 (en) 2017-05-29
JP6743106B2 (ja) 2020-08-19
NZ705820A (en) 2015-11-27
RS61447B1 (sr) 2021-03-31
CR20130551A (es) 2014-02-21
EP3505528A1 (en) 2019-07-03
WO2012145697A1 (en) 2012-10-26
EP3816288A3 (en) 2021-07-14
IL228874A0 (en) 2013-12-31
CA2833766A1 (en) 2012-10-26
KR102055331B1 (ko) 2019-12-12
EP3312189A1 (en) 2018-04-25
US20140107184A1 (en) 2014-04-17
KR20200110822A (ko) 2020-09-25
PE20181267A1 (es) 2018-08-03
US20160046945A1 (en) 2016-02-18
MX347253B (es) 2017-04-20
IL268257A (en) 2019-09-26
US20130035366A1 (en) 2013-02-07
CL2013003053A1 (es) 2014-08-08
CN106191060A (zh) 2016-12-07
RU2013151843A (ru) 2015-05-27
CA2833766C (en) 2022-05-17
JP6042871B2 (ja) 2016-12-14
KR20140026498A (ko) 2014-03-05
US20140357701A1 (en) 2014-12-04
HRP20210244T1 (hr) 2021-04-30

Similar Documents

Publication Publication Date Title
DK3505528T3 (da) Modulation af hepatitis-b-virus (hbv)-ekspression
IL269662A (en) Hepatitis C virus inhibitors
DK2398794T3 (da) Hæmmere af hepatitis C-virus
EP2854832A4 (en) MODULATION OF HEPATITIS B-VIRUS CCCDNS TRANSCRIPTION
IL227789A0 (en) Hepatitis c virus inhibitors
IL229270A0 (en) Hepatitis c virus inhibitors
DK3456831T3 (da) Målrettet modifikation af rottegenom
IL225853A0 (en) Inhibitors of hepatitis c virus
DK3461895T3 (da) Modulation af ube3a-ats-ekspression
DK2897611T3 (da) Fremgangsmåder til behandling af hepatitis c
DK2898890T3 (da) Stabilisering af viruspartikler
CO6940424A2 (es) Inhibidores del virus de la hepatitis c
EP2768517A4 (en) HEPATITIS C-VIRUS HEMMER
CO6821952A2 (es) Inihibidores del virus de la hepatitis c
DK3375882T3 (da) Fremstilling af viral vektor